Informatie:
Fout:
ID
12807
Beschrijving
Liposomal Cytarabine in the Treatment of Central Nervous System Resistant or Relapsed Acute Lymphoblastic Leukemia in Children; ODM derived from: https://clinicaltrials.gov/show/NCT01593488
Link
https://clinicaltrials.gov/show/NCT01593488
Trefwoorden
Versies (1)
- 21-12-15 21-12-15 -
Geüploaded op
21 december 2015
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Acute Lymphoblastic Leukemia NCT01593488
Eligibility Acute Lymphoblastic Leukemia NCT01593488
- StudyEvent: Eligibility
Similar models
Eligibility Acute Lymphoblastic Leukemia NCT01593488
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Age
Item
age < 18 years
boolean
C0001779 (UMLS CUI [1])
all
Item
diagnosis of acute lymphoblastic leukemia (all)
boolean
C0023449 (UMLS CUI [1])
cns leukemia
Item
central nervous system involvement with malignant cells present in cerebrospinal fluid
boolean
C1332884 (UMLS CUI [1])
recurrent disease
Item
cns involvement may be refractive to prior systemic therapy, a first recurrence after prior systemic and intrathecal therapy or a second recurrence
boolean
C0277556 (UMLS CUI [1])
cns involvement may be an isolated lesion or present with other sites of disease
Item
cns involvement may be an isolated lesion or present with other sites of disease
boolean
C0346429 (UMLS CUI [1])
C0023449 (UMLS CUI [2])
C0023449 (UMLS CUI [2])
ecog performance status
Item
ecog performance status 0-2
boolean
C1520224 (UMLS CUI [1])
life expectancy
Item
life expectancy of at least 8 weeks
boolean
C0023671 (UMLS CUI [1])
organ dysfunction
Item
absence of severe organ dysfunction
boolean
C0349410 (UMLS CUI [1])
informed consent
Item
informed consent
boolean
C0021430 (UMLS CUI [1])
eligibility for aieop studies
Item
eligibility for aieop studies of first recurrence of all,and receiving therapy in a center participating in the aieop studies
boolean
C0013893 (UMLS CUI [1,1])
C0173324 (UMLS CUI [1,2])
C0173324 (UMLS CUI [1,2])
study subject participation status
Item
concurrent treatment with experimental therapies
boolean
C2348568 (UMLS CUI [1])
neurologic toxicities
Item
severe neurologic toxicities from previous chemotherapy
boolean
C3160947 (UMLS CUI [1])
coagulopathy
Item
severe coagulopathy at time of recurrence
boolean
C0005779 (UMLS CUI [1])
sepsis
Item
sepsis
boolean
C0243026 (UMLS CUI [1])
intrathecal therapy
Item
intrathecal therapy within 1 week of planned study therapy
boolean
C1831734 (UMLS CUI [1])
radiation therapy
Item
total body or head and spine radiation within 8 weeks of enrolment
boolean
C0205918 (UMLS CUI [1])
bone marrow transplant
Item
bone marrow transplant within 8 weeks of start of study therapy.
boolean
C0005961 (UMLS CUI [1])